ArticleEuropean radiology2023
Usefulness of [
Article in European radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Diagnostic Performance of Radiolabelled FAPI Versus [International journal of molecular sciences · 2025Pooled it
- Diagnostic performance of [Frontiers in medicine · 2025Pooled it
- Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics-Where We Are at and Where We Are Heading: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Head-to-head comparison ofFrontiers in oncology · 2023Pooled it
- Same-day dual-tracer PET/CT imaging with [Annals of nuclear medicine · 2025Trial
- Gastrointestinal cancer with indeterminateOncology letters · 2026Article
- Fibroblast Activation Protein Inhibitor (FAPI) PET: A Scoping Review of Emerging Oncologic and Fibroinflammatory Applications.Diagnostics (Basel, Switzerland) · 2026Review
- [Abdominal radiology (New York) · 2026Article
- Diagnostic Efficacy of FAPI-PET/CT Versus [Diagnostics (Basel, Switzerland) · 2026Review
- Article
- Review
- The impact of FAPI PET on staging and management in patients with digestive system tumors: a systematic review and meta-analysis.Quantitative imaging in medicine and surgery · 2026Article
- Benign and malignant uptake in the postoperative diagnosis of gastrointestinal tumors: a comparative study ofQuantitative imaging in medicine and surgery · 2025Article
- Comparison of the diagnostic value of [European journal of nuclear medicine and molecular imaging · 2025Article
- Comparison ofJournal of cancer research and clinical oncology · 2025Article
- Prognostic and diagnostic value of [European radiology · 2025Article
- Evaluating the diagnostic performance of [European radiology · 2025Article
- FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer?Annals of nuclear medicine · 2025Review
- Evaluating the diagnostic value ofJapanese journal of radiology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo assess and compare the diagnostic performance of gallium-68-labelled fibroblast activation protein inhibitor ([
methodsFifty-one patients who underwent both [
resultsIn patient-based analysis, [
conclusions[ KEY POINTS: • [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.